Suzhou Basecare Medical (HKSE:02170) ROA %: -13.61% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02170 Suzhou Basecare Medical Corp Ltd HKSE:02170
70 GF Score
Price HK$1.40
GF Value HK$2.94
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Suzhou Basecare Medical ROA %?

Suzhou Basecare Medical HKSE:02170 70 ROA % is -13.61% as of Dec. 2025. GuruFocus rates HKSE:02170 with a GF Score™ of 70/100 and a GF Value™ of HK$2.94 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Suzhou Basecare Medical ranks worse than 70.73% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Suzhou Basecare Medical's annualized Net Income for the quarter that ended in Dec. 2025 was HK$-225.3 Mil. Suzhou Basecare Medical's average Total Assets over the quarter that ended in Dec. 2025 was HK$1,655.4 Mil. Therefore, Suzhou Basecare Medical's annualized ROA % for the quarter that ended in Dec. 2025 was -13.61%.

The historical rank and industry rank for Suzhou Basecare Medical's ROA % or its related term are showing as below:

HKSE:02170' s ROA % Range Over the Past 10 Years
Min: -356.41   Med: -14.04   Max: -6.53
Current: -14.46

During the past 8 years, Suzhou Basecare Medical's highest ROA % was -6.53%. The lowest was -356.41%. And the median was -14.04%.

HKSE:02170's ROA % is ranked worse than
70.73% of 854 companies
in the Medical Devices & Instruments industry
Industry Median: 0.525 vs HKSE:02170: -14.46

Suzhou Basecare Medical  (HKSE:02170) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-225.316/1655.386
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-225.316 / 291.498)*(291.498 / 1655.386)
=Net Margin %*Asset Turnover
=-77.3 %*0.1761
=-13.61 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Suzhou Basecare Medical ROA % Related Terms


Suzhou Basecare Medical ROA % Historical Data

* Premium members only.

The historical data trend for Suzhou Basecare Medical's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Basecare Medical ROA % Chart

Suzhou Basecare Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial -13.47 -6.53 -10.32 -13.12 -14.61

Suzhou Basecare Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.49 -12.87 -13.45 -15.20 -13.61

HKSE:02170 vs ABT, SYK, MDT: ROA % Comparison

For the Medical Devices subindustry, Suzhou Basecare Medical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Basecare Medical ROA % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's ROA % distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's ROA % falls into.


HKSE:02170
70GF Score
Suzhou Basecare Medical Corp Ltd HKSE:02170
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Basecare Medical ROA % Calculation

Suzhou Basecare Medical's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-246.856/( (1782.245+1597.921)/ 2 )
=-246.856/1690.083
=-14.61 %

Suzhou Basecare Medical's annualized ROA % for the quarter that ended in Dec. 2025 is calculated as:

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-225.316/( (1712.851+1597.921)/ 2 )
=-225.316/1655.386
=-13.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -13.61% mean?
Suzhou Basecare Medical (HKSE:02170) has a ROA % of -13.61% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Suzhou Basecare Medical and its competitors. According to the industry distribution chart, Suzhou Basecare Medical ranks #604 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 70.7%.
Is Suzhou Basecare Medical's ROA % too high?
Suzhou Basecare Medical's current ROA % is -13.61%. Based on the distribution chart, Suzhou Basecare Medical ranks #604 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Suzhou Basecare Medical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Suzhou Basecare Medical ranks #604 out of 854 companies for ROA %. This places Suzhou Basecare Medical in the lower half of its industry. The industry median ROA % is 0.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.53, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Suzhou Basecare Medical and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current ROA % is -13.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.94, compared to a current price of HK$1.40 — trading 52.4% below its estimated fair value. The current ROA % is -13.61%. Suzhou Basecare Medical's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current ROA % is -13.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued. The current stock price of HK$1.40 is trading 52.4% below its estimated GF Value™ of HK$2.94. GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.

Key valuation signals for HKSE:02170:

  • ROA %: -13.61%
  • GF Value™: HK$2.94 vs. price of HK$1.40 (52.4% below fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Basecare Medical Business Description

Address No. 77 Jingu Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
70GF Score

Get the complete analysis for HKSE:02170

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.40
Price
HK$2.94
GF Value